Literature DB >> 16874884

Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.

Luciana Lofego Goncalves1, Alberto Queiroz Farias, Patrícia Lofego Gonçalves, Elbio-Antonio D'Amico, Flair José Carrilho.   

Abstract

Ophthalmological complications with interferon therapy are usually mild and reversible, not requiring the withdrawal of the treatment. We report a case of a patient who had visual loss probably associated with interferon therapy. Chronic hepatitis C virus infection (genotype 1a) was diagnosed in a 33-year old asymptomatic man. His past medical history was unremarkable and previous routine ophthalmologic check-up was normal. Pegylated interferon alpha and ribavirin were started. Three weeks later he reported painless reduction of vision. Ophthalmologic examination showed extensive intraretinal hemorrhages and cotton-wool spots, associated with inferior branch retinal vein thrombosis. Antiviral therapy was immediately discontinued, but one year later he persists with severely decreased visual acuity. This case illustrates the possibility of unpredictable and severe complications during pegylated interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16874884      PMCID: PMC4125659          DOI: 10.3748/wjg.v12.i28.4602

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  5 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Interferon-associated combined branch retinal artery and central retinal vein obstruction.

Authors:  Juan E Rubio; Steve Charles
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

3.  Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.

Authors:  S Sugano; T Suzuki; M Watanabe; K Ohe; K Ishii; T Okajima
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

Review 4.  Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature.

Authors:  A Nadir; A Amin; N Chalisa; D H van Thiel
Journal:  J Viral Hepat       Date:  2000-11       Impact factor: 3.728

Review 5.  Hypercoagulability syndromes.

Authors:  R H Thomas
Journal:  Arch Intern Med       Date:  2001-11-12
  5 in total
  7 in total

Review 1.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

2.  Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon.

Authors:  Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Arlene Drack; Todd Margolis; Michael X Repka
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

3.  Irreversible anterior ischemic optic neuropathy complicating interferon alpha and ribaverin therapy.

Authors:  Hassan Seddik; Mouna Tamzaourte; Fadoua Rouibaa; Maha Fadlouallah; Ahmed Benkirane
Journal:  Int J Hepatol       Date:  2010-12-19

4.  Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis.

Authors:  Hee Young Kang; Min Chul Shin
Journal:  Korean J Ophthalmol       Date:  2012-03-22

5.  The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis.

Authors:  Mehrdad Afarid; Hamid Lashkarizadeh; Mohammad J Ashraf; Mohammad Hossein Nowroozzadeh; Sayed M Shafiee
Journal:  Indian J Ophthalmol       Date:  2016-05       Impact factor: 1.848

6.  Transient visual loss in a hepatitis C patient treated with pegylated interferon alfa-2a and ribavirin.

Authors:  Ligita Jancoriene; Dovile Norvydaite; Saulius Galgauskas; Evelina Balciunaite
Journal:  Hepat Mon       Date:  2014-02-20       Impact factor: 0.660

Review 7.  Ocular side effects of antirheumatic medications: a qualitative review.

Authors:  Clara M Castillejo Becerra; Yue Ding; Beatrice Kenol; Andrew Hendershot; Alexa Simon Meara
Journal:  BMJ Open Ophthalmol       Date:  2020-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.